Table 1. Percentage of human cell... | American Society of Hematology

Table 1.

Percentage of human cell engraftment and transduction in NOD-SCID mice

	Engraftment					Transduction
	No verapamil	Verapamil	P	No verapamil	Verapamil	P
6-8 wk after primary transplantation
BM CD45	1.2 ± 0.8	2.2 ± 1.1	.439	31 ± 15	81 ± 22	.003
BM CD34	0.3 ± 0.2	0.3 ± 0.0	.312	26 ± 24	55 ± 35	.170
BM CD33	0.6 ± 0.6	0.6 ± 0.3	.315	29 ± 24	77 ± 37	.038
BM CD19	0.7 ± 0.5	1.5 ± 1.0	.459	31 ± 18	85 ± 12	.001
14 wk after primary transplantation + αIL-2Rβ Ab
BM CD45	71 ± 23	70 ± 4	.987	19 ± 9	81 ± 9	.005
BM CD34	18 ± 5	13 ± 1	.335	20 ± 13	85 ± 12	.011
BM CD33	9 ± 2	12 ± 2	.279	29 ± 8	73 ± 13	.017
BM CD19	50 ± 16	51 ± 1	.977	27 ± 19	89 ± 3	.022
Spl CD45	24 ± 20	17 ± 2	.737	34 ± 8	79 ± 5	.006
Spl CD19	27 ± 19	28 ± 13	.946	35 ± 8	97 ± 3	.002
8 wk after secondary transplantation
BM CD45	0.2 ± 0.2	0.1 ± 0.2	.936	19 ± 13	78 ± 27	.039
BM CD33	0.1 ± 0.1	0.0 ± 0.0	.495	16 ± 13	44 ± 10	.079
BM CD19	0.1 ± 0.1	0.1 ± 0.1	.724	27 ± 26	99 ± 1	.035

	Engraftment					Transduction
	No verapamil	Verapamil	P	No verapamil	Verapamil	P
6-8 wk after primary transplantation
BM CD45	1.2 ± 0.8	2.2 ± 1.1	.439	31 ± 15	81 ± 22	.003
BM CD34	0.3 ± 0.2	0.3 ± 0.0	.312	26 ± 24	55 ± 35	.170
BM CD33	0.6 ± 0.6	0.6 ± 0.3	.315	29 ± 24	77 ± 37	.038
BM CD19	0.7 ± 0.5	1.5 ± 1.0	.459	31 ± 18	85 ± 12	.001
14 wk after primary transplantation + αIL-2Rβ Ab
BM CD45	71 ± 23	70 ± 4	.987	19 ± 9	81 ± 9	.005
BM CD34	18 ± 5	13 ± 1	.335	20 ± 13	85 ± 12	.011
BM CD33	9 ± 2	12 ± 2	.279	29 ± 8	73 ± 13	.017
BM CD19	50 ± 16	51 ± 1	.977	27 ± 19	89 ± 3	.022
Spl CD45	24 ± 20	17 ± 2	.737	34 ± 8	79 ± 5	.006
Spl CD19	27 ± 19	28 ± 13	.946	35 ± 8	97 ± 3	.002
8 wk after secondary transplantation
BM CD45	0.2 ± 0.2	0.1 ± 0.2	.936	19 ± 13	78 ± 27	.039
BM CD33	0.1 ± 0.1	0.0 ± 0.0	.495	16 ± 13	44 ± 10	.079
BM CD19	0.1 ± 0.1	0.1 ± 0.1	.724	27 ± 26	99 ± 1	.035

Data are presented as mean ± SD. Ab indicates antibody; and Spl, spleen.